Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 13/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 8/20 | 0.45 |
| ▸ | PDE4A | P27815 | 7/20 | 0.45 |
| ▸ | PDE4C | Q08493 | 6/20 | 0.45 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.45 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3129713 | 0.98 | LPAR1 (0.45) | PDE4BPDE4DPDE4APDE4CLPAR1 | |
| SCHEMBL3128234 | 0.95 | PDE4B (0.42) | PDE4BPDE4DPDE4APDE4CLPAR1 | |
| SCHEMBL3125476 | 0.90 | QPCT (0.42) | LPAR1LPAR5POLB | |
| SCHEMBL3214547 | 0.89 | PDE4A (0.58) | PDE4BPDE4DPDE4APDE4CLPAR1 | |
| SCHEMBL3192935 | 0.87 | PDE4A (0.56) | PDE4BPDE4DPDE4APDE4CLPAR1 | |
| SCHEMBL4193004 | 0.87 | PDE4A (0.52) | PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL3205063 | 0.86 | PDE4B (0.46) | PDE4BPDE4DPDE4APDE4CEPHX2 | |
| SCHEMBL3131007 | 0.85 | KMT2A (0.45) | LPAR1LPAR5POLB | |
| SCHEMBL3205698 | 0.85 | PDE4B (0.44) | PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL3131424 | 0.85 | PDE4B (0.43) | PDE4BPDE4DPDE4APDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029689-A1 | PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029689-A1 | PHOSPHODIESTERASE 4 INHIBITORS | PDE4A, PDE4B, PDE3B | PDE4B 2/4885PDE4D 9/4885PDE4A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.